Cogent Biosciences (UMRX) News Today → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free UMRX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock AnalysisCompetitorsHeadlinesSocial MediaStock AnalysisCompetitorsHeadlinesSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineCogent Biosciences Incmoney.usnews.com - April 24 at 4:34 AMAnalysts Conflicted on These Healthcare Names: Cogent Biosciences (COGT) and Altimmune (ALT)markets.businessinsider.com - February 26 at 5:33 PMAnalysts Have Conflicting Sentiments on These Healthcare Companies: Cogent Biosciences (COGT) and Moderna (MRNA)markets.businessinsider.com - February 26 at 8:53 AMCogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Resultsmarkets.businessinsider.com - February 26 at 8:53 AMBuy Rating Affirmed for Cogent Biosciences Ahead of Key Data Presentation on Bezuclastinib with Strong Upside Potentialmarkets.businessinsider.com - February 15 at 8:43 AMCogent Biosciences Stock Soars After $225M Private Placementmarketwatch.com - February 14 at 10:02 AMCogent Biosciences announces oversubscribed $225M private placementmsn.com - February 14 at 10:02 AMBuy Rating on Cogent Biosciences Amid Market Overreaction and Promising Drug Prospectsmarkets.businessinsider.com - February 9 at 2:23 AMCiti starts Cogent Biosciences at buy, cites GI tumor drug potentialmsn.com - February 8 at 4:22 PMBuy Rating Reiterated for Cogent Biosciences as Bezuclastinib Shows Promise in SUMMIT Trialmarkets.businessinsider.com - December 15 at 7:55 PMMaintaining Buy on Cogent Biosciences Amid Anticipation of Differentiating Data for Bezuclastinibmarkets.businessinsider.com - December 13 at 5:33 PMDow Surges 100 Points; Cogent Biosciences Shares Plungemarkets.businessinsider.com - December 11 at 12:21 PMCogent Biosciences Shares Fall Despite Positive Clinical Trial Updates For Systemic Mastocytosis Treatmentmarkets.businessinsider.com - December 11 at 12:21 PMCogent Reports Positive Data From Phase 2 APEX Trial Of Bezuclastinib In Systemic Mastocytosismarkets.businessinsider.com - December 11 at 10:08 AMCogent slumps after mid-stage data for rare disorder therapymsn.com - December 11 at 10:08 AMPotential Upside for Cogent Biosciences Due to Imminent Data Readout for Bezuclastinib and Underpriced Sharesmarkets.businessinsider.com - November 21 at 9:11 AMPromising Clinical Trials and Strong Financial Position Justify Buy Rating for Cogent Biosciencesmarkets.businessinsider.com - November 14 at 8:40 AMPromising Clinical Trials and Strong Financial Position Support Buy Rating for Cogent Biosciencesmarkets.businessinsider.com - November 4 at 5:21 PMPromising Market Potential for Cogent Biosciences’ Bezuclastinib Spurs Buy Ratingmarkets.businessinsider.com - October 28 at 7:55 AMAnalyst Expectations for Cogent Biosciences's Futurebenzinga.com - August 30 at 8:53 AMCogent Biosciences Is Beginning To Differentiate Its KIT Inhibitormsn.com - August 15 at 5:40 PMLifeSci Capital Remains a Buy on Cogent Biosciences (COGT)markets.businessinsider.com - August 8 at 3:59 PMDoes Cogent Biosciences, Inc. (COGT) Have the Potential to Rally 78.9% as Wall Street Analysts Expect?msn.com - July 11 at 1:47 PMCogent Biosciences Shares Rise on Fairmount Funds Management's Stake Acquisitionmarketwatch.com - June 13 at 11:04 PM9 Analysts Have This to Say About Cogent Biosciencesmarkets.businessinsider.com - June 12 at 4:10 PMCogent Biosciences (COGT) Receives a Buy from LifeSci Capitalmarkets.businessinsider.com - June 5 at 2:38 PMCogent Biosciences Reports Recent Business Highlights and First Quarter 2023 Financial Resultstechnews.tmcnet.com - May 9 at 9:11 AMBaird Initiates Coverage of Cogent Biosciences (COGT) with Outperform Recommendationmsn.com - April 29 at 8:10 AMAnalyst Ratings for Cogent Biosciencesmarkets.businessinsider.com - April 28 at 9:30 AMNeedham Maintains Cogent Biosciences (COGT) Buy Recommendationmsn.com - April 21 at 7:24 AMExpert Ratings for Cogent Biosciencesbenzinga.com - March 27 at 11:44 AMGuggenheim Reiterates Buy on Cogent Biosciences, Maintains $26 Price Targetbenzinga.com - March 17 at 1:25 PMCogent Biosciences Stock (NASDAQ:COGT), Short Interest Reportbenzinga.com - March 15 at 11:42 PMCogent Biosciences GAAP EPS of -$0.56msn.com - March 14 at 10:33 AMCogent Biosciences files for mixed shelf offering; size not disclosedmsn.com - February 10 at 6:27 PMWhat 4 Analyst Ratings Have To Say About Cogent Biosciencesbenzinga.com - January 5 at 11:43 AMCogent initiated Buy at Needham citing a better profile for cancer candidatemsn.com - December 14 at 3:38 PMCogent Biosciences Reports Recent Business Highlights and Second Quarter 2022 Financial Resultsfinance.yahoo.com - August 9 at 7:49 AMCogent Biosciences, Inc. (COGT) Is a Great Choice for "Trend" Investors, Here's Whyfinance.yahoo.com - July 28 at 2:12 PMCogent Biosciences: APEX Data Was Interesting, But We Need Moreseekingalpha.com - June 26 at 8:06 AMCogent Biosciences prices upsized $150M in stock offeringseekingalpha.com - June 14 at 7:27 AMCogent Biosciences Shares Rise After Price Target Increase, Public Offeringmarketwatch.com - June 14 at 2:26 AMCogent Biosciences Announces Proposed Public Offering of Common Stockfinance.yahoo.com - June 13 at 6:40 AMCogent Biosciences (COGT) Stock Soars 90% on Positive Clinical Datainvestorplace.com - June 10 at 4:03 PMCogent Biosciences Aces APEX TRIAL; Stock Up 35%nasdaq.com - June 10 at 10:41 AMCogent Biosciences Announces Annual Meeting of Stockholdersfinance.yahoo.com - June 2 at 9:34 AM Get Cogent Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for UMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Protect Yourself While There’s Still Time … (Ad)The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom. 4 simple steps to protect your privacy and money before it’s too late. UMRX Media Mentions By Week UMRX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. UMRX News Sentiment▼0.000.32▲Average Medical News Sentiment UMRX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. UMRX Articles This Week▼10▲UMRX Articles Average Week Get Cogent Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for UMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: NKTR News XBIT News PYXS News VSTM News PRLD News KMDA News AQST News RAPT News XOMA News AEON News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:UMRX) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersFed launches fourth dollar overhaulStansberry ResearchJeff Bezos Just Humiliated Elon MuskInvestorPlaceBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cogent Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
